Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacological activation of the p53 pathway in haematological malignancies

2 Dec 2009

Abstract excerpt

p53 gene mutations are rarely detected at diagnosis in common haematological cancers such as multiple myeloma (MM), acute myeloid leukaemia (AML), chronic lymphocytic leukaemia (CLL) and Hodgkin's disease (HD), although their prevalence may increase with progression to more aggressive or advanced stages. Therapeutic induction of p53 might therefore be particularly suitable for the treatment of haematological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer-related Molecular Pathways
Share to Retinoids in leukemia and cellular processes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19955555
DOI: 10.1136/jcp.2009.070961

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacological activation of the p53 pathway in haematological malignanciesPMID 19955555Read ↗

The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies.Semantic proximity Read ↗

Deregulation and Targeting of TP53 Pathway in Multiple MyelomaSemantic proximity Read ↗

Strategies for therapeutic targeting of the p53 pathway in cancer.Semantic proximity Read ↗

p53 as a target for the treatment of cancer.Semantic proximity Read ↗

Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be AddressedSemantic proximity Read ↗

Therapeutic Strategies to Activate p53Semantic proximity Read ↗

Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patientsSemantic proximity Read ↗

Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma.Semantic proximity Read ↗

P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myelomaSemantic proximity Read ↗

p53-targeted cancer pharmacotherapy: move towards small molecule compounds.Semantic proximity Read ↗

Awakening guardian angels: drugging the p53 pathway.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.